ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,577Medicare Part D Prescriptions Filled, Including Refills

Rank: 132 out of 917

$416K Total Retail Price of All Prescriptions

Rank: 187 out of 917

564 Patients Receiving at Least One Drug in Part D
79%Patients 65 Years and Older
51% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Washington
Lower avg

Schedule Two
Controlled Substances

17% of this provider’s 564 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

18% of this provider’s 564 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 6,486 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

15 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Washington
HYDROCODONE-ACETAMINOPHEN 329 209 S3 1 6
LISINOPRIL 311 222 2 1
OMEPRAZOLE 297 207 3 4
LEVOTHYROXINE SODIUM 286 260 4 3
SIMVASTATIN 264 235 5 2
FUROSEMIDE 253 218 6 7
WARFARIN SODIUM 202 189 7 10
METOPROLOL TARTRATE 190 157 8 11
METFORMIN HCL 178 145 9 8
AMLODIPINE BESYLATE 171 165 10 5
OXYCODONE HCL 171 97 S2 10 27
GABAPENTIN 164 138 12 17
CITALOPRAM HBR 163 125 13 15
POTASSIUM CHLORIDE 123 112 14 16
TRAZODONE HCL 112 66 15 22
HYDROCHLOROTHIAZIDE 109 92 16 9
FLUOXETINE HCL 106 47 17 38
TAMSULOSIN HCL 101 73 18 25
ATENOLOL 98 84 19 12
PANTOPRAZOLE SODIUM 95 68 20 44
MIRTAZAPINE 95 79 20 39
RANITIDINE HCL 91 74 22 29
RISPERIDONE 91 82 22 51
ZOLPIDEM TARTRATE 78 54 24 21
CARVEDILOL 75 54 25 33
LOSARTAN POTASSIUM 69 50 26 13
ATORVASTATIN CALCIUM 68 48 27 14
LOVASTATIN 67 56 28 19
CLOPIDOGREL 66 53 29 50
ALLOPURINOL 65 55 30 31
OXYCODONE-ACETAMINOPHEN 64 48 S2 31 46
FLUTICASONE PROPIONATE 63 58 32 26
MORPHINE SULFATE ER 62 0 S2 33 48
GLIPIZIDE 62 57 33 40
DONEPEZIL HCL 61 61 35 32
PREDNISONE 59 55 36 34
LANTUS 58 46 37 37
PRAVASTATIN SODIUM 58 58 37 20
PROAIR HFA 56 29 39 35
VENLAFAXINE HCL ER 54 24 40 78
SERTRALINE HCL 52 30 41 24
BUPROPION HCL SR 50 15 42 101
GLIMEPIRIDE 50 26 42 54
FENTANYL 50 35 S2 42 58
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 9, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.